Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $69,462 | $101,685 | $53,333 | $57,596 |
| % Growth | -31.7% | 90.7% | -7.4% | – |
| Cost of Goods Sold | $4,753 | $4,504 | $4,409 | $5,789 |
| Gross Profit | $64,709 | $97,181 | $48,924 | $51,807 |
| % Margin | 93.2% | 95.6% | 91.7% | 89.9% |
| R&D Expenses | $7,353 | $6,821 | $8,436 | $5,632 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $28,936 | $29,257 | $27,715 | $29,520 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $36,289 | $36,078 | $36,151 | $35,152 |
| Operating Income | $28,420 | $61,103 | $12,773 | $16,655 |
| % Margin | 40.9% | 60.1% | 23.9% | 28.9% |
| Other Income/Exp. Net | -$800 | -$1,121 | -$1,262 | -$1,433 |
| Pre-Tax Income | $27,620 | $59,982 | $11,511 | $15,222 |
| Tax Expense | -$280 | $369 | $65 | $881 |
| Net Income | $27,900 | $59,613 | $11,446 | $14,341 |
| % Margin | 40.2% | 58.6% | 21.5% | 24.9% |
| EPS | 1.547 | 3.33 | 0.64 | 0.81 |
| % Growth | -53.6% | 420.3% | -21% | – |
| EPS Diluted | 1.457 | 3.28 | 0.63 | 0.8 |
| Weighted Avg Shares Out | 18,038 | 17,885 | 17,808 | 17,647 |
| Weighted Avg Shares Out Dil | 19,156 | 18,162 | 18,169 | 17,986 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,094 | $753 | $591 | $522 |
| Interest Expense | $1,894 | $1,874 | $1,853 | $1,955 |
| Depreciation & Amortization | $603 | $607 | $604 | $604 |
| EBITDA | $30,117 | $62,463 | $13,968 | $17,781 |
| % Margin | 43.4% | 61.4% | 26.2% | 30.9% |